Vaccines - EU-27

EU-27

The Vaccines market in EU-27 is anticipated to achieve a revenue of US$12.62bn by 2024.
This is projected to exhibit a compound annual growth rate (CAGR 2024-2029) of 0.36%, leading to a market volume of US$12.85bn by 2029.
When comparing globally, United States is expected to generate the highest revenue, reaching US$29,120.00m in 2024.
Germany, as the largest economy in the EU-27, is leading the way in vaccine research and development, with multiple German companies at the forefront of innovation.

Key regions: Australia, Italy, France, South Korea, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for vaccines across the EU-27 region has been on the rise in recent years due to various factors.

Customer preferences: The preference for vaccination has increased due to the growing awareness of the importance of immunization in preventing infectious diseases. Additionally, the COVID-19 pandemic has further highlighted the need for vaccines and has led to an increase in demand for them.

Trends in the market: There has been a trend towards the development of new and innovative vaccines that are more effective and have fewer side effects. This has led to an increase in research and development activities in the region. Furthermore, there has been a shift towards the use of combination vaccines that provide protection against multiple diseases in a single shot. This has led to increased convenience for patients and reduced healthcare costs.

Local special circumstances: The vaccination policies and regulations vary across the EU-27 region. Some countries have mandatory vaccination policies, while others have voluntary policies. This has led to differences in the demand for vaccines across the region. Additionally, there are differences in the availability and accessibility of vaccines in different countries, which has also affected the demand for vaccines.

Underlying macroeconomic factors: The increasing population and the aging population in the EU-27 region have contributed to the growing demand for vaccines. Additionally, the rising healthcare expenditure and the increasing prevalence of chronic diseases have also led to an increase in the demand for vaccines. The COVID-19 pandemic has also had a significant impact on the vaccines market, with increased funding for research and development of vaccines and a surge in demand for COVID-19 vaccines.In conclusion, the vaccines market in the EU-27 region is growing due to the increasing awareness of the importance of immunization, the development of new and innovative vaccines, and the impact of the COVID-19 pandemic. However, the varying vaccination policies and regulations and the differences in the availability and accessibility of vaccines in different countries have led to differences in the demand for vaccines across the region.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.